| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10041784 | HBV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS10041785 | HBV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS30009838 | HIV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS30011116 | HIV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS30016681 | HIV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS30016680 | HIV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS30009839 | HIV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS30085762 | HIV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS30072171 | HIV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
| TVIS30072172 | HIV | ENSG00000097007.20 | protein_coding | ABL1 | Yes | No | 25 | P00519 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ABL1 |
|---|---|
| DrugBank ID | DB04868 |
| Drug Name | Nilotinib |
| Target ID | BE0000014 |
| UniProt ID | P00519 |
| Regulation Type | inhibitor |
| PubMed IDs | 17929114; 17715389; 16721371; 19920925; 19822896 |
| Citations | Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22.@@Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22.@@Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 Jun 19;94(12):1765-9. Epub 2006 May 23.@@Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F: Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009 Sep 21;3:89-101.@@Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M: Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. |
| Groups | Approved; Investigational |
| Direct Classification | Benzanilides |
| SMILES | CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F |
| Pathways | Nilotinib Inhibition of BCR-ABL |
| PharmGKB | PA165958345 |
| ChEMBL | CHEMBL255863 |
